121 related articles for article (PubMed ID: 30024911)
1. Diagnostic algorithm for determining primary tumor sites using peritoneal fluid.
Park CK; Malinowski DP; Cho NH
PLoS One; 2018; 13(7):e0199715. PubMed ID: 30024911
[TBL] [Abstract][Full Text] [Related]
2. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
[TBL] [Abstract][Full Text] [Related]
3. Seminal vesicle carcinoma presenting with malignant ascites.
Hewer E; Banz Y; Knecht U; Dettmer MS; Vassella E
Diagn Cytopathol; 2020 Aug; 48(8):785-786. PubMed ID: 32352654
[No Abstract] [Full Text] [Related]
4. PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy.
Wang Y; Wang Y; Li J; Yuan Z; Yuan B; Zhang T; Cragun JM; Kong B; Zheng W
J Hematol Oncol; 2013 Aug; 6():60. PubMed ID: 23958394
[TBL] [Abstract][Full Text] [Related]
5. p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system.
Carvalho JC; Thomas DG; McHugh JB; Shah RB; Kunju LP
Histopathology; 2012 Mar; 60(4):597-608. PubMed ID: 22260386
[TBL] [Abstract][Full Text] [Related]
6. Epithelial and organ-related marker expression in pituitary adenomas.
Cykowski MD; Takei H; Baskin DS; Rivera AL; Powell SZ
Neuropathology; 2016 Aug; 36(4):354-64. PubMed ID: 26991787
[TBL] [Abstract][Full Text] [Related]
7. NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract, and other CK7+ carcinomas: potential use for determining site of origin.
Woodard AH; Yu J; Dabbs DJ; Beriwal S; Florea AV; Elishaev E; Davison JM; Krasinskas AM; Bhargava R
Am J Clin Pathol; 2011 Sep; 136(3):428-35. PubMed ID: 21846919
[TBL] [Abstract][Full Text] [Related]
8. Value of PAX8 and WT1 Immunostaining in Confirming the Ovarian Origin of Metastatic Carcinoma in Serous Effusion Specimens.
Zhao L; Guo M; Sneige N; Gong Y
Am J Clin Pathol; 2012 Feb; 137(2):304-9. PubMed ID: 22261458
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive analysis of PAX8 expression in human epithelial tumors.
Laury AR; Perets R; Piao H; Krane JF; Barletta JA; French C; Chirieac LR; Lis R; Loda M; Hornick JL; Drapkin R; Hirsch MS
Am J Surg Pathol; 2011 Jun; 35(6):816-26. PubMed ID: 21552115
[TBL] [Abstract][Full Text] [Related]
10. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma.
McKnight R; Cohen C; Siddiqui MT
Cancer Cytopathol; 2010 Oct; 118(5):298-302. PubMed ID: 20572292
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotypic and prognostic analysis of PAX8 and TTF-1 expressions in neuroendocrine carcinomas of thymic origin: A comparative study with their pulmonary counterparts.
Bi Y; Deng Y; Li S; Zhou X; Chen Y; Ma D; Mao X; Guan Y; Chen J; Meng Y
J Surg Oncol; 2016 Nov; 114(6):697-702. PubMed ID: 27761900
[TBL] [Abstract][Full Text] [Related]
12. Differentiating primary and extragenital metastatic mucinous ovarian tumours: an algorithm combining PAX8 with tumour size and laterality.
Hu A; Li H; Zhang L; Ren C; Wang Y; Liu Y; Liu C
J Clin Pathol; 2015 Jul; 68(7):522-8. PubMed ID: 25827135
[TBL] [Abstract][Full Text] [Related]
13. PAX2 and PAX8: useful markers for metastatic effusions.
Waters L; Crumley S; Truong L; Mody D; Coffey D
Acta Cytol; 2014; 58(1):60-6. PubMed ID: 24334997
[TBL] [Abstract][Full Text] [Related]
14. Paired box gene 8, HBME-1, and cytokeratin 19 expression in preoperative fine-needle aspiration of papillary thyroid carcinoma: diagnostic utility.
Schmitt AC; Cohen C; Siddiqui MT
Cancer Cytopathol; 2010 Aug; 118(4):196-202. PubMed ID: 20731005
[TBL] [Abstract][Full Text] [Related]
15. Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma.
de Cristofaro T; Di Palma T; Soriano AA; Monticelli A; Affinito O; Cocozza S; Zannini M
Oncotarget; 2016 Jul; 7(27):41929-41947. PubMed ID: 27259239
[TBL] [Abstract][Full Text] [Related]
16. Significance analysis of PAX8 expression in endometrial carcinoma.
Hu S; Gan H; Yang F
Medicine (Baltimore); 2022 Oct; 101(42):e31159. PubMed ID: 36281161
[TBL] [Abstract][Full Text] [Related]
17. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.
Vang R; Gown AM; Zhao C; Barry TS; Isacson C; Richardson MS; Ronnett BM
Am J Surg Pathol; 2007 Jun; 31(6):854-69. PubMed ID: 17527072
[TBL] [Abstract][Full Text] [Related]
18. Unexpected PAX8 Immunoreactivity in Metastatic High-grade Breast Cancer.
Kilgore MR; Bosch DE; Adamson KH; Swanson PE; Dintzis SM; Rendi MH
Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):637-643. PubMed ID: 30358609
[TBL] [Abstract][Full Text] [Related]
19. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study.
Tacha D; Zhou D; Cheng L
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):293-9. PubMed ID: 21285870
[TBL] [Abstract][Full Text] [Related]
20. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
